Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: PF-02341272; PF-2341272; PNU-100480; U 100480; U 101244; U 101603

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator John Hopkins University; Pharmacia Corporation
  • Developer Sequella
  • Class Acetamides; Amides; Antibacterials; Oxazolidinones; Small molecules; Thiamorpholines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 29 Jun 2017 Global Alliance for TB Drug Development plans a phase I trial for Tuberculosis (In volunteers) in USA, in September 2017 (NCT03199313)
  • 04 Apr 2017 Sutezol is still in phase I trials for Tuberculosis in USA (Sequella email, April 2017)
  • 04 Apr 2017 Sutezol is still in phase II trials for Tuberculosis in South Africa (Sequella email, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top